The investment, which is carried out through a new share issue, will enable NorthX to accelerate its U.S. expansion plans, including facility enhancement, service line growth and commercial reach.

“This investment accelerates NorthX Biologics’ expansion strategy, particularly in the U.S. market. Signet Healthcare Partners brings valuable expertise in scaling biopharmaceutical companies, and we're excited to partner with them to establish NorthX as a leading global biologics development and manufacturing organisation,” says Mark Quick, Partner at Flerie.

Read NorthX Biologics full press release here: News & Events | Biologics News | NorthX Biologics

Following the transaction, Flerie will remain the majority shareholder in NorthX Biologics.

For more information:
Mark Quick
Email: ir@flerie.com

Flerie in brief
Flerie is an active long-term life science investor, with a broad and diversified portfolio of innovative companies based on pioneering science. We invest in product development and commercial growth opportunities globally alongside other leading investors, focusing predominantly on private companies that are otherwise difficult to access. Flerie’s active ownership model, broad network and resources support and accelerate the development of the portfolio projects, creating value for shareholders. Flerie AB’s ordinary share is listed on Nasdaq Stockholm with the ticker FLERIE. For further information please visit www.flerie.com